By Steve Poile
With 110 deals announced, the second quarter continued on from the strong start for life science M&A during 2014.
- 110 M&A deals announced during Q2, 2014, up from 84 M&A deals during Q1, 2014.
- The top 40 deals had a combined value of $154 billion, up from $42 billion in Q1
- The leading M&A deal of Q2, 2014 was the acquisition of Shire Pharmaceuticals by Abbvie in a deal valued at $54 billion.
- Eleven deals had value of or exceeding $1 billion, up from 4 deals in Q1.
- Most Q2, 2014 M&A deals involved big biotech and big pharma companies snapping up smaller companies in order to bolster pipeline and capabilities.
- An increasing number of deals are now incorporating contingent payments based on the future success of acquired company assets in achieving market launch and commercial success.
- Pfizer announced and subsequently terminated its proposed acquisition of AstraZeneca for $106 billion due to stakeholder opposition.
The following is a summary of the key M&A deals trends of Q2, 2014 including most active acquirers, industry and therapy focus of acquired companies. There’s also full details of the top 10 life science M&A deals by deal value including acquired company, acquirer, headline value and other financials, industry sector and therapy area focus of the acquired company, plus link to full deal record supplied by our proprietary deals and alliances database.
The remaining part of this article is Premium content – see below for access options.
Purchase this article
$35.00 BUY NOW
For $35.00, purchase this 6,439-word article and receive immediate online access.
100% Satisfaction Guarantee.